A method of treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject, said method comprising administering a compound of formula I to said subject in an amount sufficient to alleviate the symptoms or progress of said disease, wherein said compound of formula I is of the structure:
- wherein:
- T is selected from the group consisting of CHO, COR8, and C(OH)R1R2;
- R1 and R2 are independently selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, CF3, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl;
- R3 is selected from the group consisting of hydrogen, lower alkyl and substituted lower alkyl;
- R4 is selected from the group consisting of (CF3)nalkyl, (CF3)n(substituted alkyl), (CF3)nalkylphenyl, (CF3)nalkyl(substituted phenyl), and (F)ncycloalkyl;
- n=1-3;
- R5 is selected from the group consisting of hydrogen, halogen, CF3, diene fused to Y when Y═C, and substituted diene fused to Y when Y═C;
- W, Y and Z are independently selected from the group consisting of C, CR6 and N with the proviso that at least one of W or Y or Z must be C;
- R6 is selected from the group consisting of hydrogen, halogen, lower alkyl, and substituted lower alkyl;
- X is selected from the group consisting of O, S, SO2, and NR7;
- R7 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, and substituted phenyl;
- and
- R8 is selected from the group consisting of lower alkyl, CF3, phenyl, and substituted phenyl;
- or a pharmaceutically acceptable salt, hydrate, or prodrug thereof.